The use of spray-drying to enhance celecoxib solubility

References

• Martin P, Bustamante A, Chun AHC. (1993). Physical Pharmacy. Philadelphia, PA: Lippincott Williams & Wilkins.
   Google Scholar
• Geis GS. (1999). Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? Scand J Rheumatol Suppl, 109:31–37.
   PubMedGoogle Scholar
• Fort J. (1999). Celecoxib, a COX-2-specific inhibitor: the clinical data. Am J Orthop, 28:13–18.
   PubMedGoogle Scholar
• Davies NM, Gudde TW, de Leeuw MA. (2001). Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis. Expert Opin Pharmacother, 2:139–152.
   PubMedGoogle Scholar
• Moore PA, Hersh EV. (2001). Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc, 132:451–456.
   PubMed Web of Science ®Google Scholar
• Tindall E. (1999). Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. J Am Osteopath Assoc, 99:S13–S17.
   PubMedGoogle Scholar
• Tibble JA, Sigthorsson G, Foster R, Bjarnason I. (2000). Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand J Gastroenterol, 35:802–807.
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula SP, Kompella UB. (2004). Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res, 21:1797–1804.
   PubMed Web of Science ®Google Scholar
• Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B et al. (2001). Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther, 297:638–645.
   PubMed Web of Science ®Google Scholar
• Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. (2006). Single periocular injection of celecoxib–PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci, 47:1149–1160.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413–420.
   PubMed Web of Science ®Google Scholar
• Banga S, Chawla G, Varandani D, Mehta BR, Bansal AK. (2007). Modification of the crystal habit of celecoxib for improved processability. J Pharm Pharmacol, 59:29–39.
   PubMed Web of Science ®Google Scholar
• Subramanian N, Ray S, Ghosal SK, Bhadra R, Moulik SP. (2004). Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull, 27:1993–1999.
   PubMed Web of Science ®Google Scholar
• Dixit RP, Nagarsenker MS. (2007). In vitro and in vivo advantage of celecoxib surface solid dispersion and dosage form development. Indian J Pharm Sci, 69:370–377.
   Google Scholar
• Nagarsenker MS, Joshi MS. (2005). Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage. Drug Dev Ind Pharm, 31:169–178.
   PubMed Web of Science ®Google Scholar
• Gupta VR, Mutalik S, Patel MM, Jani GK. (2007). Spherical crystals of celecoxib to improve solubility, dissolution rate and micromeritic properties. Acta Pharm, 57:173–184.
   PubMedGoogle Scholar
• Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR et al. (2007). Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci, 96:2686–2702.
   PubMed Web of Science ®Google Scholar
• Pouton CW. (2006). Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci, 29:278–287.
   PubMed Web of Science ®Google Scholar
• Kolter K. (2002). Kollicoat IR®—innovation in instant release film coating. BASF ExAct, 8:4–5.
   Google Scholar
• Punitha S, Karthikeyan D, Devi P, Vedha Hari BN. (2009). Enhancement of solubility and dissolution of celecoxib by solid dispersion technique. J Pharm Sci Technol, 2:63–68.
   Google Scholar
• Chawla G, Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. (2003). Characterization of solid-state forms of celecoxib. Eur J Pharm Sci, 20:305–317.
   PubMed Web of Science ®Google Scholar
• Thimmasetty J, Subrahmanyam CVS, Vishwanath BA, Sathesh Babu PR. (2009). Solubility parameter estimation of celecoxib by current methods. Asian J Res Chem, 2:188–195.
   Google Scholar
• Vasu Dev R, Shashi Rekha K, Vyas K, Mohanti SB, Rajender Kumar P, Om Reddy G. (1999). Celecoxib, a COX-II inhibitor. Acta Cryst, C55:IUC9900161 [doi:10.1107/S0108270199098200].
   Web of Science ®Google Scholar
• Qian XF, Yin J, Guo XX, Yang YF, Zhu ZK, Lu J. (2000). Polymer–inorganic nanocomposites prepared by hydrothermal method: PVA/ZnS, PVA/CdS, preparation and characterization. J Mater Sci Letters, 19:2235–2237.
   Google Scholar
• Biswal S, Sahoo J, Murthy PN. (2009). Characterization of gliclazide–PEG 8000 solid dispersions. Trop J Pharm Res, 8:417–424.
   Web of Science ®Google Scholar
• Gupta P, Bansal AK. (2005). Devitrification of amorphous celecoxib. AAPS Pharmscitech, 6:E223–E230.
   PubMed Web of Science ®Google Scholar
• Puria V, Dantuluria AK, Kumarb M, Kararb N, Bansal AK. (2010). Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug. Eur J Pharm Sci, 40:84–93.
   PubMed Web of Science ®Google Scholar
• Yassin AE, Alanazi FK, El-Badry M, Alsarra IA, Barakat NS, Alanazi FK. (2009). Preparation and characterization of spironolactone-loaded gelucire microparticles using spray-drying technique. Drug Dev Ind Pharm, 35:297–304.
   PubMed Web of Science ®Google Scholar
• Shimpi SL, Mahadik KR, Paradkar AR. (2009). Study on mechanism for amorphous drug stabilization using gelucire 50/13. Chem Pharm Bull, 57:937–942.
   PubMed Web of Science ®Google Scholar
• Dordunoo SK, Ford JL, Rubinstein MH. (1991). Preformulation studies on solid dispersions containing triamterene or temazepam in polyethylene glycols or gelucire 44/14 for liquid filling of hard gelatin capsules. Drug Dev Ind Pharm, 17:1685–1713.
   Web of Science ®Google Scholar
• Leuner C, Dressman J. (2000). Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm, 50:47–60.
   PubMed Web of Science ®Google Scholar
• Passerini N, Perissutti B, Moneghini M, Voinovich D, Albertini B, Cavallari C et al. (2002). Characterization of carbamazepine–gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasounds. J Pharm Sci, 91:699–707.
   PubMed Web of Science ®Google Scholar
• Hancock BC, Zografi G. (1997). Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci, 86:1–12.
   PubMed Web of Science ®Google Scholar
• El-Badry M, Fetih G, Fathy M. (2009). Improvement of solubility and dissolution rate of indomethacin by solid dispersions in gelucire 50/13 and PEG4000. Saudi Pharm J, 17:217–225.
   PubMedGoogle Scholar
• Karavas E, Georgarakis E, Sigalas MP, Avgoustakis K, Bikiaris D. (2007). Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug–polymer interactions. Eur J Pharm Biopharm, 66:334–347.
   PubMed Web of Science ®Google Scholar